Results 121 to 130 of about 1,054 (155)
Testing Rimegepant for Migraine—Time to Revise the Trial Design? [PDF]
Lancet, The, 2020 We read with interest the results of the phase 3 trial by Robert Croop and colleagues1 on the use of rimegepant for treatment of acute migraine. We feel that this study, like other similarly designed trials, has major problems in its methods, which suggests caution should be taken when examining the results.
Sara Gasparini +2 more
exaly +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 2020
The orally disintegrating tablet (ODT) formulation of rimegepant (NURTEC ODT®) is a small molecule, highly-selective, calcitonin gene-related peptide antagonist that was developed by Biohaven Pharmaceutical Holding Company Ltd as an acute treatment for migraine. A conventional tablet formulation of the drug is being investigated for the acute treatment
openaire +2 more sources
The orally disintegrating tablet (ODT) formulation of rimegepant (NURTEC ODT®) is a small molecule, highly-selective, calcitonin gene-related peptide antagonist that was developed by Biohaven Pharmaceutical Holding Company Ltd as an acute treatment for migraine. A conventional tablet formulation of the drug is being investigated for the acute treatment
openaire +2 more sources
Rimegepant for the prevention and treatment of migraine
Prescriber, 2023Rimegepant (Vydura) is an oral CGRP inhibitor for the treatment of acute migraine and prevention of episodic migraine. This article discusses its indications, dosing and clinical trial outcomes.
openaire +1 more source
Rimegepant for the Acute and Preventive Treatment of Migraine: A Narrative Review of the Evidence
Expert Review of NeurotherapeuticsRimegepant is an oral small-molecule calcitonin gene-related peptide receptor antagonist approved in several countries for acute treatment of migraine and preventive treatment of episodic migraine in adults. This review summarizes the evidence, published to date, for the use of rimegepant as an acute or preventive treatment of migraine.A brief overview
Lars Edvinsson
exaly +3 more sources
Expert Review of Neurotherapeutics
Rimegepant and atogepant, two innovative oral medications for the treatment of migraine, are gaining prominence in the treatment of migraine. However, outside of specialist headache centers, these novel medications remain subjectively underutilized. While multiple rationales exist describing their underutilization, a leading factor is the complexity ...
Paolo Martelletti +2 more
exaly +3 more sources
Rimegepant and atogepant, two innovative oral medications for the treatment of migraine, are gaining prominence in the treatment of migraine. However, outside of specialist headache centers, these novel medications remain subjectively underutilized. While multiple rationales exist describing their underutilization, a leading factor is the complexity ...
Paolo Martelletti +2 more
exaly +3 more sources
Rimegepant Orally Disintegrating Tablet for Acute Migraine Treatment: A Review
Annals of Pharmacotherapy, 2020Objective To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of rimegepant for treatment of migraine. Data Sources A comprehensive PubMed and Cochrane search (1985 to May 2020) was performed utilizing ...
Alicia Potter DeFalco +2 more
openaire +2 more sources